However, BRAF mutations and RET and NTRK fusions, major markers for molecularly targeted therapies in thyroid carcinoma [26–28], are considered early molecular events in thyroid carcinogenesis [1, 29–31], which may indicate their presence in lymph node metastases similar to their primary lesions. This evidence concerns the gene BRAF and thyroiditis.